343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA
Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Ex-99.1
Investor Presentation
Director Departures - Margaret FitzPatrick and Dr. Joanne Curley Not Standing...
Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
FY 2025
Q3
Q2
Q1
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence